RECBIO-B (02179) announced its annual results for the period ending December 31, 2025. The company reported revenue of 12.726 million yuan. The loss attributable to shareholders was 610 million yuan, an increase of 8.54% compared to the previous year. The loss per share was 1.15 yuan.
The company currently has a portfolio of more than 10 vaccines. This includes two strategic products: REC610, a novel adjuvant recombinant shingles vaccine, which is currently at the stage of marketing application in China; and REC603, a recombinant nine-valent HPV vaccine, which is currently in Phase III clinical trials.
Through years of investment and focus in this field, the company has developed an integrated vaccine innovation engine. This includes a novel adjuvant platform, a protein engineering platform, an immunology evaluation platform, and a process development platform. These platforms enable the company to continuously discover and develop innovative vaccines, applying advanced technologies across its vaccine candidates.
The company is one of the few firms with the capability to research and develop novel adjuvants, allowing it to benchmark against all novel adjuvants currently approved by the FDA. The company's four major technology platforms create synergies in antigen design and optimization, adjuvant development and production, and in determining the optimal combination of antigens and adjuvants.
The company has also established an Integrated Product Development (IPD) system, enabling it to advance the research and development of multiple vaccine candidates simultaneously. Following its OPTI vaccine development philosophy, the company has built a portfolio comprising more than 10 candidate vaccines.
The company began establishing its production capacity at an early stage, aiming to ensure the smooth transition of its vaccine candidates into successful commercial products. In Taizhou, Jiangsu Province, the company has completed construction of an HPV vaccine production base that meets World Health Organization Prequalification (WHO PQ) standards. The facility has a designed annual production capacity of 20 million doses of the nine-valent HPV vaccine. It is currently in the trial production phase, aligned with the clinical progress of the nine-valent HPV vaccine to support a Biologics License Application (BLA) in China.
Furthermore, in November 2021, the company completed construction of an innovative vaccine production base based on a CHO cell expression system and successfully obtained a vaccine production license issued by the Jiangsu Provincial Medical Products Administration. This production base has consistently received statements of compliance issued by a European Union Qualified Person (QP) for multiple years. The total floor area of this base is approximately 17,000 square meters and it can be used to produce several innovative vaccines, including the novel adjuvant recombinant shingles vaccine, using CHO cells.
Comments